UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
HUMACYTE, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
44486Q 103
(CUSIP Number)

Laura E. Niklason
Brady W. Dougan
Ayabudge LLC
c/o Humacyte, Inc.
2525 E NC Highway 54
Durham, North Carolina 27713
(919) 313-9633

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 15, 2022
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

        
SCHEDULE 13D
CUSIP No. 44486Q 103 Page 2 of 7 Pages
1
NAME OF REPORTING PERSONS

Laura E. Niklason
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
3 SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
PF and OO
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

0
8
SHARED VOTING POWER

22,336,411 (1)
9
SOLE DISPOSITIVE POWER

0
10
SHARED DISPOSITIVE POWER

22,336,411 (1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

22,336,411 (1)
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

21.3% (2)
14
TYPE OF REPORTING PERSON (See Instructions)

IN
_______________________
(1)Consists of (i) 1,160,240 shares of the Issuer’s common stock held by Dr. Niklason, (ii) 1,703,507 shares of the Issuer’s common stock subject to options exercisable within 60 days of September 15, 2022 held by Dr. Niklason, (iii) 510,161 shares of the Issuer’s common stock held by Mr. Dougan, (iv) 32,499 shares of the Issuer’s common stock subject to options exercisable within 60 days of September 15, 2022 held by Mr. Dougan, (v) 18,930,004 shares of the Issuer’s common stock held by Ayabudge LLC. Dr. Niklason is married to Mr. Dougan and Mr. Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Dr. Niklason may be deemed to share beneficial ownership of the securities held of record by Mr. Dougan and Ayabudge LLC.
(2)Based upon 103,006,803 shares of the Issuer’s Common Stock outstanding as of August 22, 2022, as reported in the Issuer’s Registration Statement on Form S-3 (File No. 333-267225) (the “Form S-3”) filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2022.


    


        
CUSIP No. 44486Q 103 Page 3 of 7 Pages
1
NAME OF REPORTING PERSONS

Brady W. Dougan
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
3 SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
PF and OO
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION

United States of America
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

0
8
SHARED VOTING POWER

22,336,411 (1)
9
SOLE DISPOSITIVE POWER

0
10
SHARED DISPOSITIVE POWER

22,336,411 (1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

22,336,411 (1)
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

21.3% (2)
14
TYPE OF REPORTING PERSON (See Instructions)

IN
_______________________
(1)Consists of (i) 510,161 shares of the Issuer’s common stock held by Mr. Dougan, (ii) 32,499 shares of the Issuer’s common stock subject to options exercisable within 60 days of September 15, 2022 held by Mr. Dougan, (iii) 1,160,240 shares of the Issuer’s common stock held by Dr. Niklason, (iv) 1,703,507 shares of the Issuer’s common stock subject to options exercisable within 60 days of September 15, 2022 held by Dr. Niklason and (v) 18,930,004 shares of the Issuer’s common stock held by Ayabudge LLC. Mr. Dougan is married to Dr. Niklason and Mr. Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Mr. Dougan may be deemed to share beneficial ownership of the securities held of record by Dr. Niklason and Ayabudge LLC.
(2)Based upon 103,006,803 shares of the Issuer’s Common Stock outstanding as of August 22, 2022, as reported in the Form S-3 filed with the SEC on September 1, 2022.
    


        

CUSIP No. 44486Q 103 Page 4 of 7 Pages
1
NAME OF REPORTING PERSONS

Ayabudge LLC
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
3 SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)

AF and BK
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware, United States of America
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER

0
8
SHARED VOTING POWER

18,930,004 (1)
9
SOLE DISPOSITIVE POWER

0
10
SHARED DISPOSITIVE POWER

18,930,004 (1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

18,930,004 (1)
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

18.4% (2)
14
TYPE OF REPORTING PERSON (See Instructions)

OO

_______________________
(1)Consists of 18,930,004 shares of the Issuer’s common stock held by Ayabudge LLC. Mr. Dougan is the sole member of Ayabudge LLC and has sole voting and dispositive power over the shares held by Ayabudge LLC. Ayabudge LLC has pledged 18,930,004 shares to certain lenders in connection with a financing arrangement.
(2)Based upon 103,006,803 shares of the Issuer’s Common Stock outstanding as of August 22, 2022, as reported in the Form S-3 filed with the SEC on September 1, 2022.
    



CUSIP No. 44486Q 103 Page 5 of 7 Pages

This Amendment No. 1 to the statement on Schedule 13D (this “Statement”) with respect to the shares of common stock, par value $0.0001 per share (the “Common Stock”), of Humacyte, Inc. (the “Issuer”), filed by Laura E. Niklason (“Dr. Niklason”), Brady W. Dougan (“Mr. Dougan”) and Ayabudge LLC (“Ayabudge” and, together with Dr. Niklason and Mr. Dougan, the “Reporting Persons”) on August 30, 2021 (such statement, as amended herein the “Schedule 13D”), amends the Schedule 13D as set forth below.
All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. Except as specifically amended by this Amendment No. 1, items in the Schedule 13D remain unchanged.
Item 3.    Source and Amount of Funds or Other Consideration
Item 3 of the Schedule 13D is hereby amended to be supplemented by the following:
On September 15, 2022, Ayabudge sold 1,522,500 shares of Common Stock in a block trade at a price of $4.00 per share for an aggregate sale price of approximately $6.1 million (excluding commissions). The purchaser was an existing investor of the Issuer, who had previously participated in the Issuer's PIPE financing transaction, and was interested in increasing its ownership of the Issuer. Mr. Dougan used the proceeds of the transaction to pay down leverage while providing a mechanism for the purchaser to acquire a large block of shares at a time that the Issuer was not conducting a financing transaction.
On September 15, 2022, Dr. Niklason purchased 2,000 shares of Common Stock on the open market at a price of $4.14 per share for an aggregate purchase price of approximately $8,000 (excluding commissions). Dr. Niklason used personal funds for such acquisition.
On May 23, 2022, Dr. Niklason purchased 10,000 shares of Common Stock on the open market at a price of $4.83 per share for an aggregate purchase price of approximately $48,000 (excluding commissions). Dr. Niklason used personal funds for such acquisition.
On December 16, 2021, Mr. Dougan sold 75,000 shares of Common Stock on the open market at a weighted average price of $9.00 per share for an aggregate sale price of approximately $675,000 (excluding commissions).
On December 15, 2021, Mr. Dougan sold 125,000 shares of Common Stock on the open market at a weighted average price of $8.885 per share for an aggregate sale price of approximately $1.1 million (excluding commissions).
On December 14, 2021, Mr. Dougan sold 23,694 shares of Common Stock and 76,306 shares of Common Stock on the open market at weighted average prices of $9.798 and $9.325 per share, respectively, for an aggregate sale price of approximately $944,000 (excluding commissions).
Item 5.    Interest in Securities of the Issuer
Item 5 of the Schedule 13D is hereby amended and restated in full as follows:
(a)-(b)    
Number of shares of Common Stock beneficially owned:
Laura E. Niklason, M.D., Ph.D.
  22,336,411 shares
Brady W. Dougan
  22,336,411 shares
Ayabudge LLC
18,930,004 shares


        

CUSIP No. 44486Q 103 Page 6 of 7 Pages

Percent of class:
Laura E. Niklason, M.D., Ph.D.   21.3%
Brady W. Dougan   21.3%
Ayabudge LLC 18.4%
The percentage ownership was calculated based upon 103,006,803 shares of the Issuer’s Common Stock outstanding as of August 22, 2022, as reported in the Form S-3 filed with the SEC on September 1, 2022.
Number of shares as to which such person has:
 
(i) Sole power to vote or to direct the vote:
 
Laura E. Niklason, M.D., Ph.D.   0 shares
Brady W. Dougan   0 shares
Ayabudge LLC 0 shares
 
(ii) Shared power to vote or to direct the vote:
 
Laura E. Niklason, M.D., Ph.D.   22,336,411 shares
Brady W. Dougan   22,336,411 shares
Ayabudge LLC 18,930,004 shares

(iii) Sole power to dispose or to direct the disposition of:
 
Laura E. Niklason, M.D., Ph.D.   0 shares
Brady W. Dougan   0 shares
Ayabudge LLC 0 shares

(iv) Shared power to dispose or to direct the disposition of:
 
Laura E. Niklason, M.D., Ph.D.   22,336,411 shares
Brady W. Dougan   22,336,411 shares
Ayabudge LLC 18,930,004 shares

(c)    Except as reported in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty (60) days.
(d)    Not applicable.
(e)    Not applicable.




        

CUSIP No. 44486Q 103 Page 7 of 7 Pages

SIGNATURE
After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Date: September 19, 2022     Laura E. Niklason
    By:  
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
   
Date: September 19, 2022     Brady W. Dougan
    By:  
/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact
   
Date: September 19, 2022     Ayabudge LLC
    By:  
/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact
    Name: Brady W. Dougan
Title: Sole Member


Humacyte (NASDAQ:HUMA)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Humacyte Charts.
Humacyte (NASDAQ:HUMA)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Humacyte Charts.